A5025977781- Immune cells in cancer
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Pancreatic and Hepatic Oncology Research
- Nanoplatforms for cancer theranostics
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Multiple Myeloma Research and Treatments
- Phagocytosis and Immune Regulation
- Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Nanoparticle-Based Drug Delivery
- Chronic Myeloid Leukemia Treatments
- Cell Adhesion Molecules Research
- Cancer Immunotherapy and Biomarkers
- Inflammatory Biomarkers in Disease Prognosis
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Hematopoietic Stem Cell Transplantation
- Extracellular vesicles in disease
- Advanced biosensing and bioanalysis techniques
- interferon and immune responses
- Chemokine receptors and signaling
- Cancer Genomics and Diagnostics
- Protein Degradation and Inhibitors
- CAR-T cell therapy research
- Cancer Research and Treatments
Advanced Centre for Treatment, Research and Education in Cancer
2018-2024
Tata Memorial Hospital
2016-2024
Homi Bhabha National Institute
2019-2024
University of Miami
2021-2024
Indian Institute of Science Education and Research Pune
2015-2024
University of Massachusetts Amherst
2020-2023
John Wiley & Sons (United States)
2021
Savitribai Phule Pune University
2006-2020
Istituto Nazionale di Fisica Nucleare, Sezione di Milano
2018
National University of Singapore
2007
Abstract We have shown that KRAS–TP53 genomic coalteration is associated with immune-excluded microenvironments, chemoresistance, and poor survival in pancreatic ductal adenocarcinoma (PDAC) patients. By treating cooperativity as a model for high-risk biology, we now identify cell-autonomous Cxcl1 key mediator of spatial T-cell restriction via interactions CXCR2+ neutrophilic myeloid-derived suppressor cells human PDAC using imaging mass cytometry. Silencing cell-intrinsic...
Abstract We accrued 201 patients of adult AML treated with conventional therapy, in morphological remission, and evaluated MRD using sensitive error-corrected next generation sequencing (NGS-MRD) multiparameter flow cytometry (FCM-MRD) at the end induction (PI) consolidation (PC). Nearly 71% were PI NGS-MRD + 40.9% PC (median VAF 0.76%). had a significantly higher cumulative incidence relapse ( p = 0.003), inferior overall survival 0.001) free < as compared to − patients. was predictive...
Flow-cytometric minimal residual disease (FC-MRD) monitoring is a well-established risk-stratification factor in B-lymphoblastic leukemia/lymphoma (-B-ALL) and being considered as basis for deintensification or escalation treatment protocols. However, currently practiced standard FC-MRD has limited sensitivity (up to 0.01%) higher false MRD-negative rate. Hence, highly sensitive, widely applicable, easily reproducible assay needed, which can provide reliable therapeutic modifications.A...
Multiparametric flow cytometry (MFC) is a popular technique for minimal residual disease (MRD) analysis. However, its applicability still limited to 90% of B-cell precursor acute lymphoblastic leukemia (BCPALL) due two major issues, i.e. proportion cases do not express adequate associated immunophenotype (LAIPs) with currently used markers and drug-induced antigen modulation. Hence, the incorporation additional reliable required further improvement MFC-based MRD evaluation. We studied...
Biotin-conjugated multistimuli-responsive polysaccharide vesicular nanocarriers are designed and developed, for the first time, to accomplish receptor-mediated endocytosis in cancer cells deliver anticancer drugs intracellular compartments. For this purpose, a new renewable hydrophobic unit was custom with redox-degradable disulfide enzyme-biodegradable aliphatic ester chemical linkages, it conjugated along biotin on dextran backbone. The derivative self-assembled into nanovesicles of <200...
New cisplatin-stitched polysaccharide vesicular nanocarrier is developed for combination therapy of three clinical important antagonistic drugs together to accomplish synergistic cancer in breast treatment. Carboxylic functionalized dextran was tailor-made the chemical conjugation cisplatin, and a renewable hydrophobic unit anchored backbone interdigitize chains self-assemble as nanovesicles. Water-soluble DNA-intercalating drug doxorubicin·HCl (DOX) water insoluble topoisomerase type I...
Partial/complete pathologic response following neoadjuvant chemotherapy (NAC) in pancreatic cancer (PDAC) patients undergoing pancreatectomy is associated with improved survival. We sought to determine whether neutrophil-to-lymphocyte ratio (NLR) dynamics predict PDAC, and if manipulating NLR impacts chemosensitivity preclinical models uncovers potential mechanistic underpinnings underlying these effects. Pathologic PDAC (n=94) NAC (7/2015-12/2019) was dichotomized as partial/complete or...
The analysis of expressed sequence tag (EST) datasets offers a rapid and cost-effective approach to elucidate the transcriptome an organism, but requiring several computational methods for assembly annotation. ESTExplorer is comprehensive workflow system EST data management analysis. pipeline uses 'distributed control approach' in which most appropriate bioinformatics tools are implemented over different dedicated processors. Species-specific repeat masking conceptual translation in-built....
Background Recently, anti-CD38 monoclonal antibody (Mab) therapy has become a focus of attention as an additional/alternative option for many hematological neoplasms including T-cell acute lymphoblastic leukemia (T-ALL). It been shown that antitumor efficacy anti-CD38-Mab depends on the level CD38 expression tumor cells. Reports in T-ALL are scarce, and data effect cytotoxic chemotherapy limited to very few samples. Moreover, it lacks entirely refractory disease adult T-ALL. We report flow...
An enzyme-responsive FRET nanoprobe was designed and developed based on AIE-driven fluorescent polysaccharide polymersomes to study the real-time delivery aspects in intracellular compartments live cancer cells.
Background: Measurable/minimal residual disease (MRD) status is suggested as a powerful indicator of clinical-outcome in T-cell lymphoblastic leukemia/lymphoma (T-ALL). Contrary to B-cell ALL, reports on T-ALL MRD are limited and mostly based molecular methods, mainly from developed countries. Multicolor flow cytometry (MFC)-based studies very few. Clinically relevant cut-off levels ideal time-point for assessment still inconclusive. In view lack data the developing world, we evaluated...
The accurate estimation of drug release kinetics polymeric vehicles is an indispensable prerequisite for the developments successful carriers cancer therapy. present investigation reports development time-resolved fluorescence spectroscopic approach real-time fluorophore loaded polysaccharide vesicles that are potential vectors in treatment. were custom designed with appropriate enzyme and pH responsiveness water-soluble biocompatible Rhodamine B (Rh-B). semipermeable membrane dialysis...
Measurable/minimal residual disease (MRD) status has been suggested as a powerful indicator of clinical-outcome in T-cell lymphoblastic leukemia/lymphoma (T-ALL). Multicolor flow cytometric (MFC)-based T-ALL MRD reports are limited and traditionally based on the utilization markers-of-immaturity like TdT CD99. Moreover, studies demonstrating multicolor (MFC) approach for assessment sparse. Herein, we describe an 11-marker, 10-color MFC-based method using "approach exclusion."The study...
Multicolor flow cytometry (MFC) is crucial in detecting occult or minimal bone marrow (BM) involvement by non-Hodgkin lymphomas (NHL), which may not be detected using trephine biopsy imaging studies. Detection of low-level BM can challenging without definite immunophenotypic aberrancies. We studied the utility CD305 MFC detection B-NHL, especially absence aberrancies commonly used markers. The study included 1084 consecutive samples submitted for staging B-NHLs (excluding CLL) over two...
Abstract Introduction In 2016, Children Oncology Group (COG) described a new high‐risk subtype of acute myeloid leukemia (AML) with distinct immunophenotypic‐signature, RAM‐phenotype (RAM‐AML). Data on clinical and laboratory features RAM‐AML are still limited to COG report only. Herein, we the clinicopathological characteristics detailed immunophenotypic patients. report, 38% belonged megakaryoblastic (AMKL)‐subtype. Hence, further compared non‐RAM‐AMKL diagnosed during same study period....
Measurable residual disease (MRD) assessment using multicolor flow cytometry (MFC) has become the center point of pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) risk stratification and therapeutic management. The addition new markers can improve accuracy applicability MFC-based MRD assay further. Herein, we evaluated utility a marker, CD304/neuropilin-1, in MRD.Expression patterns CD304 were studied leukemic blasts from BCP-ALL patients normal B cells (NPBC) uninvolved...
T-cell/NK-cell non-Hodgkin's lymphoma (T/NK-NHL) is an uncommon heterogeneous group of diseases. The current classification T/NK-NHL mainly based on histopathology and immunohistochemistry. In practice, however, the lack unique histopathological patterns, overlapping cytomorphology, immunophenotypic complexity, inadequate panels, diverse clinical presentations pose a great challenge. Flow cytometric immunophenotyping (FCI) gold standard for diagnosis, subtyping, monitoring many hematological...
Background Current flow‐cytometric plasma cell (PC) gating is based on CD138, CD38, and CD45 expression. CD138 known for variable expression loss during storage processing. Introduction of anti‐CD38 anti‐CD138 monoclonal‐antibody therapies has limited the use these markers follow‐up. Hence, additional reliable PC‐gating are required. Recently, CD229 been claimed as an alternative marker. However, studies to a small cohort samples. We evaluated utility new marker in routine laboratory...
Introduction: One of the mainstays chemotherapy in acute myeloid leukemia (AML) is induction with a goal to achieve morphological complete remission (CR). However, not all patients by this criterion long-term and subset relapse. This relapse explained presence measurable residual disease (MRD). Methods: We accrued 451 consecutive adult AML (from March 2012 December 2017) after informed consent. All received standard chemotherapy. MRD testing was done at post-induction and, if feasible,...
MicroRNAs are small, non-coding RNA molecules that becoming popular biomarkers in several diseases. However, their low abundance serum/plasma poses a challenge exploiting potential clinics. Several commercial kits available for rapid isolation of microRNA from plasma. reports guiding the selection appropriate to study downstream assays scarce. Hence, we compared four evaluate microRNA-extraction plasma and provided modified protocol further improved superior kit's performance.We (miRNeasy...
Measurable residual disease (MRD) is the most relevant predictor of disease-free survival in B-cell acute lymphoblastic leukemia (B-ALL). We aimed to establish a highly sensitive flow cytometry (MFC)-based B-ALL-MRD (BMRD) assay for patients receiving anti-CD19 immunotherapy with an alternate gating approach and document prevalence immunophenotype recurrently occurring low-level mimics confounding populations.We standardized 15-color highly-sensitive BMRD CD19-free approach. The study...